| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A case of Elexacaftor-Tezacaftor-Ivacaftor induced rash resolving without interruption of treatment
|
Bhaskaran, Divyalakshmi
|
|
|
21 |
6 |
p. 1077-1079
|
artikel
|
| 2 |
Advent of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis treatment: What consequences on Aspergillus-related diseases? Preliminary insights
|
Chesnay, Adélaïde
|
|
|
21 |
6 |
p. 1084-1085
|
artikel
|
| 3 |
Angiographic and histopathological study on bronchial-to-pulmonary vascular anastomoses on explants from patients with cystic fibrosis after bronchial artery embolisation
|
Habert, Paul
|
|
|
21 |
6 |
p. 1042-1047
|
artikel
|
| 4 |
A restructuring of microbiome niche space is associated with Elexacaftor-Tezacaftor-Ivacaftor therapy in the cystic fibrosis lung
|
Sosinski, Lo M.
|
|
|
21 |
6 |
p. 996-1005
|
artikel
|
| 5 |
Association between early respiratory viral infections and structural lung disease in infants with cystic fibrosis
|
Sanders, Don B.
|
|
|
21 |
6 |
p. 1020-1026
|
artikel
|
| 6 |
Association between elevated peripheral blood eosinophil count and respiratory outcomes in adults with cystic fibrosis
|
Ye, Si Cong
|
|
|
21 |
6 |
p. 1048-1052
|
artikel
|
| 7 |
Availability of CFTR modulators in countries of Eastern Europe: The reality in 2022
|
Drevinek, Pavel
|
|
|
21 |
6 |
p. 1082-1083
|
artikel
|
| 8 |
Clinical outcomes in cystic fibrosis at 6 years of age with tricare insurance coverage
|
Collaco, Joseph M.
|
|
|
21 |
6 |
p. 984-987
|
artikel
|
| 9 |
Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding
|
Jain, Raksha
|
|
|
21 |
6 |
p. 1074-1076
|
artikel
|
| 10 |
Considerations for CF airway infection sampling and impact of CFTR modulators
|
Caverly, Lindsay J.
|
|
|
21 |
6 |
p. 906-907
|
artikel
|
| 11 |
Dose adjustments of Elexacaftor/Tezacaftor/Ivacaftor in response to mental health side effects in adults with cystic fibrosis
|
Spoletini, G.
|
|
|
21 |
6 |
p. 1061-1065
|
artikel
|
| 12 |
Drug-induced acne with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis
|
Hudson, Brionna N.
|
|
|
21 |
6 |
p. 1066-1069
|
artikel
|
| 13 |
Early Pseudomonas aeruginosa predicts poorer pulmonary function in preschool children with cystic fibrosis
|
Aurora, P.
|
|
|
21 |
6 |
p. 988-995
|
artikel
|
| 14 |
ECFS standards of care on CFTR-related disorders: Diagnostic criteria of CFTR dysfunction
|
Sermet-Gaudelus, I.
|
|
|
21 |
6 |
p. 922-936
|
artikel
|
| 15 |
ECFS standards of care on CFTR-related disorders: Updated diagnostic criteria
|
Castellani, C
|
|
|
21 |
6 |
p. 908-921
|
artikel
|
| 16 |
Editorial Board
|
|
|
|
21 |
6 |
p. ii
|
artikel
|
| 17 |
Effects of ivacaftor on systemic inflammation and the plasma proteome in people with CF and G551D
|
Hoppe, Jordana E.
|
|
|
21 |
6 |
p. 950-958
|
artikel
|
| 18 |
Eruptive melanocytic naevi following initiation of elexacaftor/ivacaftor/tezacaftor for cystic fibrosis
|
Atkinson, Michael
|
|
|
21 |
6 |
p. 1070-1073
|
artikel
|
| 19 |
Factors in childhood associated with lung function decline to adolescence in cystic fibrosis
|
Begum, Nelufa
|
|
|
21 |
6 |
p. 977-983
|
artikel
|
| 20 |
Impact of azithromycin on serum inflammatory markers in children with cystic fibrosis and new Pseudomonas
|
Pittman, Jessica E
|
|
|
21 |
6 |
p. 946-949
|
artikel
|
| 21 |
Is CF airway inflammation still relevant in the era of highly effective modulators?
|
Bengtson, Charles D.
|
|
|
21 |
6 |
p. 901-903
|
artikel
|
| 22 |
Macrophage PD-1 associates with neutrophilia and reduced bacterial killing in early cystic fibrosis airway disease
|
Margaroli, Camilla
|
|
|
21 |
6 |
p. 967-976
|
artikel
|
| 23 |
Magnetic resonance imaging detects improvements of pulmonary and paranasal sinus abnormalities in response to elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis
|
Wucherpfennig, Lena
|
|
|
21 |
6 |
p. 1053-1060
|
artikel
|
| 24 |
Measuring the effect of elexacaftor/tezacaftor/ivacaftor combination therapy on the respiratory pump in people with CF using dynamic chest radiography
|
FitzMaurice, Thomas S
|
|
|
21 |
6 |
p. 1036-1041
|
artikel
|
| 25 |
Mucus and mucus flake composition and abundance reflect inflammatory and infection status in cystic fibrosis
|
Markovetz, Matthew R.
|
|
|
21 |
6 |
p. 959-966
|
artikel
|
| 26 |
New concepts in antimicrobial resistance in cystic fibrosis respiratory infections
|
Drevinek, Pavel
|
|
|
21 |
6 |
p. 937-945
|
artikel
|
| 27 |
News Article
|
|
|
|
21 |
6 |
p. 899-900
|
artikel
|
| 28 |
Pathological remodeling of distal lung matrix in end-stage cystic fibrosis patients
|
Pinezich, Meghan R.
|
|
|
21 |
6 |
p. 1027-1035
|
artikel
|
| 29 |
Predicting risk-adjusted incidence rates of methicillin-resistant Staphylococcus Aureus and Pseudomonas Aeruginosa in cystic fibrosis programs in the United States
|
Stoudemire, William
|
|
|
21 |
6 |
p. 1013-1019
|
artikel
|
| 30 |
Research letter: The impact of elexacaftor/tezacaftor/ivacaftor on adherence to nebulized maintenance therapies in people with cystic fibrosis
|
Song, Jia Tong
|
|
|
21 |
6 |
p. 1080-1081
|
artikel
|
| 31 |
Routine clinical monitoring fails to identify children at high risk of lung function decline
|
Perrem, Lucy
|
|
|
21 |
6 |
p. 904-905
|
artikel
|
| 32 |
The lung microbiota in children with cystic fibrosis captured by induced sputum sampling
|
Weiser, Rebecca
|
|
|
21 |
6 |
p. 1006-1012
|
artikel
|
Tijdschrift beschrijving